Xtant Medical’s second-quarter sales reached $35.4 million, according to financial results posted Aug. 12.
Five notes:
1. Revenue grew 18% year over year, according to a news release.
2. The company saw net income of $3.6 million compared to a net loss of $3.9 million in the same time in 2024.
3. Highlights of the second quarter include plans to sell two spine implant lines to Companion Spine for about $19.2 million and the launch of OsteoFactor Pro.
4. Operating expenses decreased compared to the same period in 2024. Second-quarter expenses were $19.7 million in 2025 compared to $21.5 million in 2024.
5. Xtant Medical raised its 2025 guidance and expects full-year revenue to reach $131 million to $135 million.
